Announcements Trials
Browse Landscape

Status

Completed 3

Sponsor Class

OTHER 4INDUSTRY 3

Study Type

Interventional 34Observational 3

Sponsor

Cancer Type

Dermatologic 3

Conditions

Keratosis, Actinic 3Keratosis 1

Interventions

Blood Specimen Collection 31Sorafenib 29Nivolumab 29Bevacizumab 26Data Collection 24Observation 23palbociclib 22Sunitinib 22radium Ra 223 dichloride 20enzalutamide 18Rituximab 18Ipilimumab 16regorafenib 15Drug Therapy 15Trastuzumab 14Docetaxel 14ribociclib 12exemestane 12atezolizumab 12Standard of Care 12darolutamide 11apalutamide 11Leuprolide 11Capecitabine 11Afatinib 11Bortezomib 10Anastrozole 10trastuzumab deruxtecan 9pembrolizumab 9avelumab 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Observational × Imiquimod × Clear all
NCT00189254 2022-02-07

A Study to Follow up Recurrence Rates of Actinic Keratoses One Year After Completion of Study 1487-IMIQ

Viatris Inc.

Completed
72 enrolled
Dermatologic

Keratosis, Actinic

NCT02362152 2019-12-13

RAPID-ACT

LEO Pharma

Completed
1,168 enrolled
Dermatologic

Keratosis, Actinic

NCT00114023 2007-02-19

1-Year Follow up to the 1473-IMIQ Study

Graceway Pharmaceuticals, LLC

Completed
84 enrolled
Dermatologic

Keratosis, Keratosis, Actinic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡